Hepatitis C News and Research

Latest Hepatitis C News and Research

Codexis receives U.S. patent for enzymes utilized in HCV therapeutics

Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.

16 May 2012

Lab21’s HCV drug resistance genotyping receives new patents in the U.S., Europe

Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.

15 May 2012

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012

New Jefferson Hepatitis C Center

Thomas Jefferson University Hospital recently opened its new Jefferson Hepatitis C Center, one of only a few comprehensive, multidisciplinary centers dedicated to the study of hepatitis C virus and hepatic disease in the Pennsylvania, New Jersey and Delaware tri-state area.

14 May 2012

Viewpoints: Two views on how to fight obesity; Tough choices for big business on health costs

Forgive us if we don't cheer at the prospect of adding 32 million to the total number of Americans who are dozens of pounds too heavy, a count that stood in 2010 at 78 million.

11 May 2012

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

"Bacteria, viruses and parasites cause around two million cases of cancer in the world each year, experts believe," the Press Association/Guardian reports. According to the news service, "Scientists carried out a statistical analysis of cancer incidence to calculate that around 16 percent of all cancers diagnosed in 2008 were infection-related," and "the proportion of cancers linked to infection was three times higher in developing countries than in developed ones."

10 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

Treatment with IL-12 triggers T cell exhaustion in cancer patients

Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 (IL-12) has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found.

10 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

Research reveals possible strategy to reverse fibrosis in liver and other organs

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, report that significant numbers of myofibroblasts - cells that produce the fibrous scarring in chronic liver injury - revert to an inactive phenotype as the liver heals. The discovery in mouse models could ultimately help lead to new human therapies for reversing fibrosis in the liver, and in other organs like the lungs and kidneys.

8 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Reuters examines cancer in Africa

Reuters examines cancer in Africa, writing, "Most of Africa's around 2,000 languages have no word for cancer. The common perception in both developing and developed countries is that it's a disease of the wealthy world, where high-fat, processed-food diets, alcohol, smoking and sedentary lifestyles fuel tumor growth."

3 May 2012

Combination of two mTOR inhibitors stops growth of hepatocellular carcinoma

The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute.

3 May 2012

Ligand first quarter total revenues increase to $5.6 million

Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

3 May 2012

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV).

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Copenhagen Consensus report argues for addressing chronic, NCDs in developing countries

In the second part of a series of Slate articles highlighting issues being examined by the Copenhagen Consensus Center, Bjorn Lomborg, director of the center, examines the global burden of non-communicable diseases, which "receive the smallest amount of donor assistance of all health conditions, having lost ground since 1990 relative to infectious diseases," he writes.

2 May 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

Codexis receives U.S. patent for enzymes utilized in HCV therapeutics

Lab21’s HCV drug resistance genotyping receives new patents in the U.S., Europe

Sinovac first quarter sales increase 30.3% to $6.0M

New Jefferson Hepatitis C Center

Viewpoints: Two views on how to fight obesity; Tough choices for big business on health costs

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

Researchers use clever screening methods to speed vaccine production

Treatment with IL-12 triggers T cell exhaustion in cancer patients

Inovio first quarter total revenue decreases to $1.7 million

One in six cancer cases worldwide related to preventable or curable infections

Research reveals possible strategy to reverse fibrosis in liver and other organs

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

BioCryst first quarter revenues increase to $12.2 million

Alnylam first quarter revenues decrease to $20.6 million

Reuters examines cancer in Africa

Combination of two mTOR inhibitors stops growth of hepatocellular carcinoma

Ligand first quarter total revenues increase to $5.6 million

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Array BioPharma third quarter revenue increases to $19.1M

Copenhagen Consensus report argues for addressing chronic, NCDs in developing countries

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in